Neuroendocrine Tumor
📧 Sign up to get email alerts when something new happens for Neuroendocrine Tumor.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-09-10Clinical Trial Update: Octreotide LAR in the Induction of Immunologic Response in NENs Patients [Phase 2]
Phase 2 trial update evaluating octreotide LAR for inducing immunologic response in neuroendocrine tumors has completed.
-
FDA approval · 2020-09-03FDA Approved: DETECTNET — Original Application (CURIUM US LLC)
FDA approved DETECTNET (Copper-64 DOTATATE) from Curium US LLC for PET imaging of neuroendocrine tumors.
-
CLINICAL_TRIALS trial_result · 2020-08-20Clinical Trial Update: DEBOXA for Inoperable NET Liver Metastases [Phase 1, Phase 2]
Clinical trial update for DEBOXA in inoperable neuroendocrine tumor liver metastases, spanning Phase 1 and Phase 2.
-
CLINICAL_TRIALS trial_result · 2020-06-17Clinical Trial Update: Holmium-166-radioembolization in NET After Lutetium-177-dotatate; an Efficacy Study [Phase 2]
Phase 2 clinical trial update evaluating Holmium-166 radioembolization in neuroendocrine tumors after Lutetium-177-dotatate.
-
CLINICAL_TRIALS trial_result · 2020-06-01Clinical Trial Update: Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors [Phase 2]
Pazopanib hydrochloride is being studied in a Phase 2 trial for progressive carcinoid tumors (neuroendocrine tumors); the study status is ac…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2020-05-29FDA Approved: LUTATHERA — Supplemental Application (Advanced Accelerator Applications USA, Inc)
The FDA approved a supplemental application for LUTATHERA (lutetium Lu-177 dotatate) from Advanced Accelerator Applications USA, Inc., grant…
-
CLINICAL_TRIALS trial_result · 2020-04-01Clinical Trial Update: Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression [Phase 2]
Phase 2 clinical trial evaluating peptide receptor radionuclide therapy for advanced, non-resectable or symptomatic tumors with SSTR overexp…
-
FDA approval · 2020-02-03FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved a supplemental application for octreotide acetate from Heritage Pharmaceuticals Inc. (Avet Pharmaceuticals Inc.).
-
CLINICAL_TRIALS trial_result · 2019-12-26Clinical Trial Update: Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors [Phase 2, Phase 3]
A phase 2/3 trial evaluating combination chemotherapy with bevacizumab in advanced neuroendocrine tumors has been terminated; results were p…
-
CLINICAL_TRIALS trial_result · 2019-11-12Clinical Trial Update: GA-68 DOTA-TOC of Somatostatin Positive Malignancies [Phase 1, Phase 2]
Phase 1/2 clinical trial update for GA-68 DOTA-TOC targeting somatostatin receptors in neuroendocrine tumors and related malignancies, with …
-
CLINICAL_TRIALS trial_result · 2019-09-30Clinical Trial Update: A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors [Phase 2]
Phase 2 multicenter trial evaluating 177Lu-DOTA-TATE with kidney dosimetry in patients with disseminated neuroendocrine tumors, completed.
-
FDA approval · 2019-04-11FDA Approved: SANDOSTATIN — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Sandostatin (octreotide acetate) from Novartis Pharmaceuticals Corporation under NDA 019667.
-
CLINICAL_TRIALS trial_result · 2019-03-04Clinical Trial Update: Pazopanib as Single Agent in Advanced NETs [Phase 2]
Phase 2 trial of pazopanib as a single agent in advanced/metastatic neuroendocrine tumors has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2019-01-25Clinical Trial Update: RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe [Phase 2]
Phase 2 RAMSETE trial evaluating RAD001 (everolimus) in advanced and metastatic silent neuroendocrine tumors; results were posted in January…
-
CLINICAL_TRIALS trial_result · 2019-01-18Clinical Trial Update: A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors [Phase 1]
A Phase 1 trial evaluating LY2584702 combined with erlotinib or everolimus in patients with solid tumors was terminated, and results have be…
-
CLINICAL_TRIALS trial_result · 2018-10-31Clinical Trial Update: High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors [Phase 3]
A Phase 3 trial evaluating high-dose I-131 MIBG for metastatic neuroendocrine tumors has completed.
-
FDA approval · 2018-09-27FDA Approved: NETSPOT — Supplemental Application (Advanced Accelerator Applications USA, Inc)
The FDA approved a supplemental application for NETSPOT (68GA-DOTATATE) submitted by Advanced Accelerator Applications USA, Inc.
-
FDA approval · 2018-08-27FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for Octreotide acetate from Hikma Pharmaceuticals USA.
-
FDA approval · 2018-08-09FDA Approved: NETSPOT — Supplemental Application (Advanced Accelerator Applications USA, Inc)
The FDA approved a supplemental application for NETSPOT (68Ga-DOTATATE) from Advanced Accelerator Applications USA, Inc., to modify and/or e…
-
CLINICAL_TRIALS research · 2018-07-19Clinical Trial Update: The Management of Neuroendocrine Tumours: A Nutritional Viewpoint.
A completed clinical trial examining the role of a Mediterranean diet in the management of neuroendocrine tumors.
-
CLINICAL_TRIALS trial_result · 2018-04-13Clinical Trial Update: Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion [Phase 3]
A Phase 3 clinical trial evaluating the effect of oral 5-HTP on urinary 5-HIAA excretion was terminated.
-
FDA approval · 2018-03-09FDA Approved: OCTREOTIDE — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for octreotide acetate from Fresenius Kabi USA, LLC.
-
CLINICAL_TRIALS trial_result · 2017-12-27Clinical Trial Update: AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors [Phase 2]
Phase 2 trial of AMG 479 in advanced carcinoid tumors and pancreatic neuroendocrine tumors has completed, with results posted in 2017.
-
CLINICAL_TRIALS trial_result · 2017-10-02Clinical Trial Update: A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours [Phase 3]
Phase 3 trial comparing 177Lu-DOTA0-Tyr3-Octreotate with Octreotide LAR in inoperable, progressive somatostatin receptor–positive midgut car…
-
CLINICAL_TRIALS withdrawal · 2017-08-23Clinical Trial Update: 68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors
The clinical trial evaluating 68Ga DOTA-TATE PET/CT in somatostatin receptor–positive tumors is no longer available.